Announcement on Change of Securities Affairs Representative
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Change of Securities Affairs Representative
Filed with SSE ·
6ix hasn’t read this filing yet.
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai MicuRx Pharmaceutical
- Announcement on Voluntary Disclosure of Compensation for the Patent Protection Period of the Company's Core Products
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Resignation of Directors and Senior Management Members
- Announcement on Transfer of Some of The Company's Wholly-owned Subsidiary Kerui Kaisi's Business To Four Wholly-owned Subsidiaries Including Kangyue Biology, etc.
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
Later from Shanghai MicuRx Pharmaceutical
- Announcement on Voluntary Disclosure of the Company Certified as a High-tech Enterprise
- Earnings Preannouncement for 2025
- Announcement on Voluntary Disclosure of Permission Granted by the US for the Initiation of Clinical Trials of MRX-5
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Announcement on Preliminary Earnings Estimate for 2025
Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical